Condition (MeSH)
Cystadenocarcinoma
ClinicalTrials.gov lists 17 trials for Cystadenocarcinoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 of the 17 trials are tagged with Cystadenocarcinoma itself; the rest are tagged with a narrower condition beneath it.
When did Cystadenocarcinoma trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 2 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 2 |
| 2017 | 1 |
| 2015 | 1 |
| 2014 | 2 |
| 2010 | 1 |
| 2009 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cystadenocarcinoma trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 7 |
| Phase 2/3 | 3 |
| Not applicable | 3 |
| Observational | 2 |
How many Cystadenocarcinoma trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 3 |
| Completed | 6 |
| Terminated | 3 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cystadenocarcinoma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Gynecologic Oncology Group | 1 |
| Incyte Corporation | 1 |
| K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 1 |
| Sheba Medical Center | 1 |
Which drugs are being tested for Cystadenocarcinoma? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 2 |
| NIVOLUMAB | 1 |
| GSK1120212 | 1 |
| IPILIMUMAB | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Niraparib Pill | 3 |
| Letrozol (Femara, Novartis) | 2 |
| Pegylated Liposomal Doxorubicin (PLD), Doxil | 1 |
| Conventional Chemotherapy | 1 |
| Tamoxifen Pill | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cystadenocarcinoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Small Intestinal Obstruction | 22 | 2 |
| Abdominal Pain | 19 | 2 |
| Urinary Tract Infection | 15 | 2 |
| DIARRHEA | 13 | 1 |
| FATIGUE | 10 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Cystadenocarcinoma? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| European experts consensus statement on cystic tumours of the pancreas. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2013 | Yes |
| Differentiation of cystic pancreatic neoplasms and pseudocysts by conventional and echo-enhanced ultrasound. | Journal of gastroenterology and hepatology | 2004 | Yes |
| Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. | The American journal of pathology | 1998 | Yes |
| [A case of recurrent endometrial cancer successfully treated with oral administration of etoposide]. | Gan to kagaku ryoho. Cancer & chemotherapy | 1992 | Yes |
| Primary leiomyosarcoma associated with serous cystadenocarcinoma of the ovary. | Gynecologic oncology | 1977 | Yes |
Showing 5 of 7 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.